Diastolic dysfunction and exercise capacity in patients with metabolic syndrome and overweight/obesity.

Diastolic dysfunction Doppler echocardiography Exercise capacity Metabolic syndrome Obesity

Journal

International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 13 11 2018
revised: 16 12 2018
accepted: 18 12 2018
entrez: 9 1 2019
pubmed: 9 1 2019
medline: 9 1 2019
Statut: epublish

Résumé

Left ventricle diastolic dysfunction (LVDD) is a common finding in high risk individuals, its presence being associated with reduced exercise capacity (EC). We assessed the prevalence of LVDD, applying the 2016 guidelines of the American Society of Echocardiography (ASE)/European Association of Cardiovascular Imaging (EACVI), in a population with overweight/obesity and metabolic syndrome and its association with EC. This was a prospective, cross-sectional study of a cohort of 235 patients (mean age of 65 ± 5 years old and 33% female) without heart disease and an ejection fraction >50% who underwent a complete echocardiographic assessment and cardiopulmonary exercise testing. Individuals meeting three or more criteria of the 2016 ASE/EACVI guidelines are considered to have LVDD, while tests are considered indeterminate in those meeting only two. Overall, 178 (76%) of our patients met one echocardiographic cutoff value for LVDD, 91 (39%) met two and 7 (3%) three or more. Patients meeting three cutoffs values showed a significant reduction in maximal oxygen uptake (16 ± 3 vs. 19.6 ± 5 ml/kg/min, p < .05), unlike those with indeterminate tests. In multiple regression analysis, meeting three cutoffs was associated with number of METS (ß = -2.2, p = .018). In exploratory analysis, using two criteria based on cutoffs different from those proposed in the guidelines, we identified groups with different EC. The application of 2016 ASE/EACVI guidelines limited the prevalence of LVDD to 3%. This group showed a clear reduction of the EC. New echocardiographic cutoff values proposed in this study allow us to establish subgroups with different levels of EC.

Sections du résumé

BACKGROUND BACKGROUND
Left ventricle diastolic dysfunction (LVDD) is a common finding in high risk individuals, its presence being associated with reduced exercise capacity (EC). We assessed the prevalence of LVDD, applying the 2016 guidelines of the American Society of Echocardiography (ASE)/European Association of Cardiovascular Imaging (EACVI), in a population with overweight/obesity and metabolic syndrome and its association with EC.
METHODS AND RESULTS RESULTS
This was a prospective, cross-sectional study of a cohort of 235 patients (mean age of 65 ± 5 years old and 33% female) without heart disease and an ejection fraction >50% who underwent a complete echocardiographic assessment and cardiopulmonary exercise testing. Individuals meeting three or more criteria of the 2016 ASE/EACVI guidelines are considered to have LVDD, while tests are considered indeterminate in those meeting only two. Overall, 178 (76%) of our patients met one echocardiographic cutoff value for LVDD, 91 (39%) met two and 7 (3%) three or more. Patients meeting three cutoffs values showed a significant reduction in maximal oxygen uptake (16 ± 3 vs. 19.6 ± 5 ml/kg/min, p < .05), unlike those with indeterminate tests. In multiple regression analysis, meeting three cutoffs was associated with number of METS (ß = -2.2, p = .018). In exploratory analysis, using two criteria based on cutoffs different from those proposed in the guidelines, we identified groups with different EC.
CONCLUSIONS CONCLUSIONS
The application of 2016 ASE/EACVI guidelines limited the prevalence of LVDD to 3%. This group showed a clear reduction of the EC. New echocardiographic cutoff values proposed in this study allow us to establish subgroups with different levels of EC.

Identifiants

pubmed: 30619930
doi: 10.1016/j.ijcha.2018.12.010
pii: S2352-9067(18)30169-6
pmc: PMC6314243
doi:

Types de publication

Journal Article

Langues

eng

Pagination

67-72

Références

Am Heart J. 1999 Dec;138(6 Pt 1):1033-7
pubmed: 10577432
Am J Cardiol. 2000 Feb 15;85(4):473-7
pubmed: 10728953
Am J Cardiol. 2006 Jul 1;98(1):116-20
pubmed: 16784933
Heart. 2007 Oct;93(10):1285-92
pubmed: 17890705
JAMA. 2009 Jan 21;301(3):286-94
pubmed: 19155455
Eur J Cardiovasc Prev Rehabil. 2009 Jun;16(3):249-67
pubmed: 19440156
Circulation. 2009 Jun 23;119(24):3144-61
pubmed: 19487589
Circ Cardiovasc Imaging. 2010 Jan;3(1):24-31
pubmed: 19846730
J Am Coll Cardiol. 2011 Mar 22;57(12):1368-74
pubmed: 21414533
Circulation. 2012 Feb 14;125(6):782-8
pubmed: 22261198
Echocardiography. 2012 Jul;29(6):647-51
pubmed: 22486526
Eur Heart J. 2012 Dec;33(23):2917-27
pubmed: 22952138
Am J Cardiol. 2014 Aug 1;114(3):473-8
pubmed: 24948490
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Mayo Clin Proc. 2015 Nov;90(11):1515-23
pubmed: 26455884
Korean Circ J. 2016 May;46(3):394-401
pubmed: 27275176
Eur Heart J Cardiovasc Imaging. 2016 Dec;17(12):1321-1360
pubmed: 27422899
Circ J. 2016 Nov 25;80(12):2489-2495
pubmed: 27773890
Cardiovasc Diabetol. 2017 Feb 8;16(1):21
pubmed: 28178970
Am J Cardiol. 2017 Jun 1;119(11):1846-1853
pubmed: 28391990
J Am Coll Cardiol. 2017 Apr 18;69(15):1937-1948
pubmed: 28408024
Eur Heart J Cardiovasc Imaging. 2017 Sep 1;18(9):961-968
pubmed: 28444160
Eur J Heart Fail. 2018 Jan;20(1):3-15
pubmed: 28925073
J Am Coll Cardiol. 2017 Sep 26;70(13):1618-1636
pubmed: 28935040
J Am Soc Echocardiogr. 2018 Jan;31(1):79-88
pubmed: 29111121
Eur Heart J Cardiovasc Imaging. 2018 Apr 1;19(4):380-386
pubmed: 29236978
Rev Esp Cardiol (Engl Ed). 2018 Nov;71(11):926-934
pubmed: 29258737
Diabetes Care. 2018 Nov 2;:null
pubmed: 30389673
J Appl Physiol (1985). 1993 May;74(5):2225-33
pubmed: 8335552

Auteurs

Angel M Alonso-Gómez (AM)

Department of Cardiology, Organización Sanitaria Integrada (OSI) ARABA, University Hospital Araba, Vitoria-Gasteiz, Spain.
Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Lucas Tojal Sierra (L)

Department of Cardiology, Organización Sanitaria Integrada (OSI) ARABA, University Hospital Araba, Vitoria-Gasteiz, Spain.

Elena Fortuny Frau (E)

Department of Cardiology, University Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain.

Leire Goicolea Güemez (L)

Department of Cardiology, Organización Sanitaria Integrada (OSI) ARABA, University Hospital Araba, Vitoria-Gasteiz, Spain.

Ane Aboitiz Uribarri (A)

Department of Cardiology, Organización Sanitaria Integrada (OSI) ARABA, University Hospital Araba, Vitoria-Gasteiz, Spain.

María P Portillo (MP)

Nutrition and Obesity Group, Department of Nutrition and Food Science, Faculty of Pharmacy and Lucio Lascaray Research Institute, University of País Vasco (UPV/EHU), 01006 Vitoria, Spain.
Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Estefanía Toledo (E)

University of Navarra, Department of Preventive Medicine and Public Health, Faculty of Medicine, IdiSNA, Pamplona, Spain.
Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Helmut Schröder (H)

Cardiovascular Risk and Nutrition (CARIN), Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
CIBER Epidemiologia y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.

Jordi Salas-Salvadó (J)

Human Nutrition Unit, Faculty of Medicine and Health Sciences, IISPV, Rovira i Virgili University, Reus, Spain.
Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Fernando Arós Borau (F)

Department of Cardiology, Organización Sanitaria Integrada (OSI) ARABA, University Hospital Araba, Vitoria-Gasteiz, Spain.
Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
University of the Basque Country/Euskal Herriko Univertsitatea (UPV/EHU), Department of Medicine, Medical Education Unit, Teaching Unit of Medicine, Vitoria-Gasteiz, Álava, Spain.

Classifications MeSH